Pharmacyclics (PCYC) Tops Q3 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Pharmacyclics (PCYC) PT Lifted to $175 at Nomura on Strong Q3
November 5, 2014 10:04 AM ESTNomura Securities analyst M. Ian Somaiya reiterated a Buy rating and boosted its price target on Pharmacyclics (NASDAQ: PCYC) to $175.00 (from $158.00) following strong Q3 results.
Somaiya commented, "We are increasing our Imbruvica estimates and PCYC TP to $175 from $158, following strong 3Q14 results and further... More
